Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
February 28, 2020
- Taiho Gains Japan/Asian Rights to Arcus’ Anti-PD-1 Antibody
February 28, 2020
- Opdivo Filed for 1st-Line NSCLC as Chemo Combo
February 28, 2020
- Vimpat Filed for Adjunctive Therapy for Tonic-Clonic Seizures: UCB/Daiichi Sankyo
February 28, 2020
- Hisamitsu Applies for Diclofenac Patch for Cancer Pain in Japan
February 28, 2020
- Novo Nordisk Submits Somapacitan in Japan for Adult Growth Hormone Deficiency
February 28, 2020
- MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
- Keytruda No. 1 Drug Prescribed at Acute-Care Hospitals in 2019: Survey
February 27, 2020
- AbbVie Files Humira for Pyoderma Gangrenosum in Japan
February 27, 2020
- Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
February 26, 2020
- Takeda’s ALK Drug Alunbrig Gets FDA’s Priority Status for Frontline NSCLC
February 26, 2020
- Shionogi’s Antibiotic Fetroja Now Available in US
February 26, 2020
- Kissei Takes Over Distribution of Desmopressin Brands from Ferring in Japan
February 26, 2020
- Eisai Obtains China Rights for Fuji Yakuhin's Gout Treatment Dotinurad
February 26, 2020
- Non-Japanese Players Nab 60% of Top 20 Company Sales, IQVIA Data Show
February 25, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Takeda Vaults to 9th in Global Pharma Ranking after Shire Buy, Roche Tops List: Jiho Tally
February 21, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…